Ispire Appoints Jim McCormick as CFO

News by 2FIRSTS.ai
May.21.2024
Ispire Appoints Jim McCormick as CFO
Ispire Technology Inc. appoints Jim McCormick as CFO and other senior executives to drive global expansion.

According to a press release posted on the Ispire (Ispire Technology Inc.) website on May 20, Ispire (NASDAQ stock code: ISPR) announced the appointment of Jim McCormick as Chief Financial Officer. The company also announced the appointment of John Patterson as Senior Vice President of International Nicotine, Dennis Lider as Senior Vice President of Cannabis Product Sales, and David Hessler as Senior Vice President of Operations.

 

The company's CEO, Michael Wang, stated, "We are pleased to announce this significant talent upgrade at Ispire as we prepare for rapid expansion both domestically and internationally. We are excited to welcome Jim, John, David, and Dennis to our team, as they will be valuable additions to our team. These strategic initiatives highlight our commitment to driving innovation and growth in our global development.

 

Ispire's Chief Financial Officer, Jim McCormick, stated, "As someone who has long admired Ispire's dedication to customer value, I look forward to collaborating with Michael and the executive team to further enhance Ispire's achievements not only in the United States but also in various global markets.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S FDA Announces Dec. 8 Deadline for IQOS MRTP Renewal Comments
U.S FDA Announces Dec. 8 Deadline for IQOS MRTP Renewal Comments
The U.S. FDA has set December 8, 2025, 11:59 p.m. ET as the closing date for public comments on the MRTP renewal applications submitted by Philip Morris Products S.A. for several IQOS heated tobacco products.
Nov.07 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai
JTI launches Ploom AURA new heated tobacco device device in Romania
JTI launches Ploom AURA new heated tobacco device device in Romania
Japan Tobacco International(JTI) introduces Ploom AURA in Romania, combining SMART HEATFLOW technology to preserve tobacco flavor, aiming at high-end consumers.
Oct.17 by 2FIRSTS.ai
JT Q3 2025: Revenue +18%, Profit +30%; RRP Volume +40%; Guidance Up
JT Q3 2025: Revenue +18%, Profit +30%; RRP Volume +40%; Guidance Up
Japan Tobacco (JT) delivered a strong Q3 2025. Revenue rose 18.3% year over year to ¥947.2 billion, with adjusted operating profit up 27.8% to ¥279.0 billion (+20.8% at constant currency) and net profit up 29.7% to ¥176.7 billion. Growth was led by reduced-risk products (RRP): total RRP volume climbed 40%, with heated tobacco (HTS) up 53%. In Japan, the launches of Ploom AURA and EVO pods pushed HTS category share to 15.5%, while the Ploom user base has nearly doubled versus two years ago.
Oct.30 by 2FIRSTS.ai
Russian police seize counterfeit e-cigarettes and tobacco products in Novosibirsk,products valued at about 1.3 million rubles
Russian police seize counterfeit e-cigarettes and tobacco products in Novosibirsk,products valued at about 1.3 million rubles
Russian police in Novosibirsk bust counterfeit e-cigarette and tobacco products, seizing items worth 1.3 million rubles. Consideration for criminal charges.
Oct.13 by 2FIRSTS.ai
Philip Morris USA Reaches $66M Settlement With Washington State Over MSA Payment Dispute
Philip Morris USA Reaches $66M Settlement With Washington State Over MSA Payment Dispute
Philip Morris USA has reached a settlement with Washington State and agreed to pay $66 million to resolve disputes over annual payments under the 1998 Master Settlement Agreement (MSA) for the period 2005–2015.
Nov.04 by 2FIRSTS.ai